XDR-TB transmission in London: Case management and contact tracing investigation assisted by early whole genome sequencing

Journal of Infection

Volumn 73, Issue 3, 2016, Pages 210-218

  Arnold, Amber ^a,b   Witney, Adam A ^a   Vergnano, Stephania ^a   Roche, Anita ^c   Cosgrove, Catherine A ^a,b   Houston, Angela ^b   Gould, Katherine A ^a   Hinds, Jason ^a   Riley, Peter ^b   Macallan, Derek ^a,b   Butcher, Philip D ^a   Harrison, Tom S ^a,b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Contact tracing; Disease outbreaks; Drug resistance; Pathology, molecular; Tuberculosis

Indexed keywords

RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENOME; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; CASE MANAGEMENT; CHILD; CLINICAL ARTICLE; CONTACT EXAMINATION; CONTROLLED STUDY; ENGLAND; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; FOLLOW UP; GENE SEQUENCE; HUMAN; MALE; MYCOBACTERIUM TUBERCULOSIS; WHOLE GENOME SEQUENCING; DNA SEQUENCE; DRUG EFFECTS; EPIDEMIC; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; TRANSMISSION;

ADULT; ANTITUBERCULAR AGENTS; CASE MANAGEMENT; CHILD; CONTACT TRACING; DISEASE OUTBREAKS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; GENOME, BACTERIAL; HUMANS; LONDON; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; SEQUENCE ANALYSIS, DNA;

EID: 84991111307     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2016.04.037     Document Type: Article

References (42)

1. 1 WHO, Definitions and reporting framework for tuberculosis – 2013 revision (updated December 2014). 2014, World Health Organisation, Geneva, Switzerland.
2. 2 WHO, Global tuberculosis report 2014., 2014, World Health Organisation, Geneva, Switzerland.
3. 3 Tuberculosis in England: 2015 report, 2015, Public Health England, London.
4. 4 Abubakar, I., Moore, J., Drobniewski, F., Kruijshaar, M., Brown, T., Yates, M., et al. Extensively drug-resistant tuberculosis in the UK: 1995 to 2007. Thorax 64:6 (2009), 512–515.
5. 5 Falzon, D., Gandhi, N., Migliori, G.B., Sotgiu, G., Cox, H., Holtz, T.H., et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respir J 42:1 (2013), 156–168.
6. 6 Van der Werf, M., Langendam, M., Sandgren, A., Manissero, D., Lack of evidence to support policy development for management of contacts of multidrug-resistant tuberculosis patients: two systematic reviews. Int J Tuberc Lung Dis 16:3 (2012), 288–296.
7. 7 Management of contacts of MDR TB and XDR TB patients, 2012, European Centre for Disease Prevention and Control, Stockholm.
8. 8 Lange, C., Abubakar, I., Alffenaar, J.-W.C., Bothamley, G., Caminero, J.A., Carvalho, A.C.C., et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 44:1 (2014), 23–63.
9. 9 WHO, Guidelines on the management of latent tuberculosis infection. 2015, World Health Organisation, Geneva, Switzerland.
10. 10 Wu, S., Zhang, Y., Sun, F., Chen, M., Zhou, L., Wang, N., et al. Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis. Am J Ther 23:2 (2016 Mar-Apr), e521–e530, 10.1097/01.mjt.0000433951.09030.5a.
11. 11 Walker, T.M., Ip, C.L., Harrell, R.H., Evans, J.T., Kapatai, G., Dedicoat, M.J., et al. Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. Lancet Infect Dis 13:2 (2013), 137–146.
12. 12 Roetzer, A., Diel, R., Kohl, T.A., Rückert, C., Nübel, U., Blom, J., et al. Whole genome sequencing versus traditional genotyping for investigation of a Mycobacterium tuberculosis outbreak: a longitudinal molecular epidemiological study. PLoS Med, 10(2), 2013, e1001387.
13. 13 Köser, C.U., Ellington, M.J., Cartwright, E., Gillespie, S.H., Brown, N.M., Farrington, M., et al. Routine use of microbial whole genome sequencing in diagnostic and public health microbiology. PLoS Pathog, 8(8), 2012, e1002824.
14. 14 Witney, A.A., Gould, K.A., Arnold, A., Coleman, D., Delgado, R., Dhillon, J., et al. Clinical application of whole-genome sequencing to inform treatment for multidrug-resistant tuberculosis cases. J Clin Microbiol 53:5 (2015), 1473–1483.
15. 15 Outhred, A.C., Jelfs, P., Suliman, B., Hill-Cawthorne, G.A., Crawford, A.B., Marais, B.J., et al. Added value of whole-genome sequencing for management of highly drug-resistant TB. J Antimicrob Chemother 70:4 (2015), 1198–1202.
16. 16 NICE, Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control, CG117. 2011, National Institute for Health and Care Excellence (NICE), London.
17. 17 Erkens, C., Kamphorst, M., Abubakar, I., Bothamley, G., Chemtob, D., Haas, W., et al. Tuberculosis contact investigation in low prevalence countries: a European consensus. Eur Respir J 36:4 (2010), 925–949.
18. 18 Helb, D., Jones, M., Story, E., Boehme, C., Wallace, E., Ho, K., et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 48:1 (2010), 229–237.
19. 19 Feasey, N., Pond, M., Coleman, D., Solomon, A., Cosgrove, C., Delgado, R., et al. Moxifloxacin and pyrazinamide susceptibility testing in a complex case of multidrug-resistant tuberculosis [Case study]. Int J Tuberc Lung Dis 15:3 (2011), 417–420.
20. 20 WHO, Guidelines for the programmatic management of drug-resistant tuberculosis. 2008, World Health Organization, Geneva, Switzerland.
21. 21 Assay service- Guidelines for use, 2011, Antimicrobial Reference Laboratory, Bristol.
22. 22 Potter, J., Capstick, T., Ricketts, W., Whitehead, N., Kon, O., A UK-based resource to support the monitoring and safe use of anti-TB drugs and second-line treatment of multidrug-resistant TB. Thorax 70:3 (2015), 297–298.
23. 23 Mase, S., Chorba, T., Lobue, P., Castro, K., Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multi-drug resistant tuberculosis. MMWR Recomm Rep 62:RR-09 (2013), 1–12.
24. 24 WHO, The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. 2013, World Health Organization, Geneva, Switzerland.
25. 25 Fox, G.J., Barry, S.E., Britton, W.J., Marks, G.B., Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J 41:1 (2013), 140–156.
26. 26 Shah, N.S., Yuen, C.M., Heo, M., Tolman, A.W., Becerra, M.C., Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 58:3 (2014), 381–391.
27. 27 Anderson, L.F., Tamne, S., Brown, T., Watson, J.P., Mullarkey, C., Zenner, D., et al. Transmission of multidrug-resistant tuberculosis in the UK: a cross-sectional molecular and epidemiological study of clustering and contact tracing. Lancet Infect Dis 14:5 (2014), 406–415.
28. 28 Small, P.M., Hopewell, P.C., Singh, S.P., Paz, A., Parsonnet, J., Ruston, D.C., et al. The epidemiology of tuberculosis in San Francisco–a population-based study using conventional and molecular methods. N Engl J Med 330:24 (1994), 1703–1709.
29. 29 Seddon, J.A., Godfrey-Faussett, P., Hesseling, A.C., Gie, R.P., Beyers, N., Schaaf, H.S., Management of children exposed to multidrug-resistant Mycobacterium tuberculosis. Lancet Infect Dis 12:6 (2012), 469–479.
30. 30 Schaaf, H.S., Garcia-Prats, A.J., Hesseling, A.C., Seddon, J.A., Managing multidrug-resistant tuberculosis in children: review of recent developments. Curr Opin Infect Dis 27:3 (2014), 211–219.
31. 31 Pontali, E., Sotgiu, G., Migliori, G.B., Management of MDR-TB household contacts: how difficult is it to climb the mountain?. Int J Tuberc Lung Dis 15:9 (2011), 1137–1138.
32. 32 Ferebee, S., Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 26 (1969), 28–106.
33. 33 Selby, C., Allen, M., Leitch, A., Optimal duration of radiological follow-up for tuberculosis contacts. Respir Med 83:4 (1989), 353–355.
34. 34 Hussain, S., Watura, R., Cashman, B., Campbell, I., Evans, M.R., Tuberculosis contact tracing: are the British Thoracic Society guidelines still appropriate?. Thorax 47:11 (1992), 984–985.
35. 35 Schaaf, H.S., Gie, R.P., Kennedy, M., Beyers, N., Hesseling, P.B., Donald, P.R., Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics 109:5 (2002), 765–771.
36. 36 Horne, N., Davies, B., Pines, A., Somner, A., Springett, V., Stradling, P., et al. A study of a standardised contact procedure in tuberculosis. Tubercle 59:4 (1978), 245–259.
37. 37 Horsburgh, C.R. Jr., Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 350:20 (2004), 2060–2067.
38. 38 Review of the tuberculosis nurse workforce, 2015, Centre for Workforce Intelligence, London.
39. 39 Tuberculosis case management and cohort review: guidance for health professionals, 2012, Royal College of Nursing, London.
40. 40 Pankhurst, L.J., del Ojo Elias, C., Votintseva, A.A., Walker, T.M., Cole, K., Davies, J., et al. Rapid, comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing: a prospective study. Lancet Respir Med 4:1 (2016 Jan), 49–58, 10.1016/S2213-2600(15)00466-X.
41. 41 Whitney, A.A., Cosgrove, C.A., Arnold, A., Hinds, J., Stoker, N.G., Butcher, P.D., Clinical use of whole genome sequencing for Mycobacterium tubercuolosis. BMC Med, 14, 2016, 46, 10.1186/s12916-016-0598-2.
42. 42 NICE, Tuberculosis. NICE guidelines NG33. 2016, National Institute for Health and Care Excellence (NICE), London.